A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils

Ohnishi, Hiroshi; Eitoku, Masamitsu; Yokoyama, Akihito

doi:10.1016/j.heliyon.2022.e09736

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a minor proportion of mepolizumab was used for COPD which was not included in the label. Despite the frequent coexistence and common pathophysiology of asthma and COPD ( Maspero et al, 2022 ), previous studies have reported inconsistent results regarding the efficacy of mepolizumab for COPD ( Drick et al, 2022 ; Ohnishi et al, 2022 ). Concerning the reporter countries, Canada and America accounted for most reports.…”

Section: Discussionmentioning

confidence: 99%

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

Li,

Wang,

Deng

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Mepolizumab has been approved by the FDA for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Real-world studies on mepolizumab-associated adverse events are limited. The present study aimed to explore mepolizumab-related adverse events based on the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.Methods: A disproportionality analysis was performed to assess the safety profile of mepolizumab based on the reports from the FAERS database between October 2015 and December 2022. Demographic information, the time to onset, the safety of long-term mepolizumab exposure as well as safety in pediatric patients were also investigated.Results: A total of 736 significant preferred terms (PTs) were identified among the 13,497 mepolizumab-associated adverse events (AEs) reports collected from the FAERS database. The frequently reported AEs including dyspnea, fatigue, and headache were in line with drug instruction and previous studies. Unexpected significant AEs such as cough, malaise, and chest discomfort were also identified. Most AEs occurred within the first month after mepolizumab initiation. Pneumonia and wheezing were frequently reported in patients with long-term mepolizumab exposure as well as in the pediatric population.Conclusion: Our results were consistent with the observations in previous clinical and real-world studies. New and unexpected AE signals of mepolizumab were also identified. Close attention should be paid to the long-term safety of mepolizumab as well as safety in the pediatric population. Prospective studies are required for optimal use of mepolizumab.

show abstract

Section: Discussionmentioning

confidence: 99%

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

Li,

Wang,

Deng

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The usual dose is 30 mg SC every 4 weeks for 3 doses and then every 8 weeks. Other recent studies have also demonstrated potential benefits with the use of benralizumab for managing further respiratory-related EAD such as chronic rhinosinusitis with nasal polyps [ 36 ] and chronic obstructive pulmonary disease (at higher doses) [ 37 ]. Table 1 depicts most of the ongoing clinical trials with benralizumab targeting several EADs other than asthma.…”

Section: Literature Reviewmentioning

confidence: 99%

The Role of Benralizumab in Eosinophilic Immune Dysfunctions: A Case Report-Based Literature Review

Gomes

Mendes

Ferreira

et al. 2023

Case Reports in Medicine

View full text Add to dashboard Cite

In the past years, the knowledge of eosinophils playing a primary pathophysiologic role in several associated conditions has led to the development of biologics targeting therapies aiming at normalizing the immune response, reducing chronic inflammation, and preventing tissue damage. To better illustrate the potential relationship between different eosinophilic immune dysfunctions and the effects of biological therapies in this scenario, here, we present a case of a 63-year-old male first referred to our department in 2018 with a diagnosis of asthma, polyposis, and rhinosinusitis and presenting a suspicion of nonsteroidal anti-inflammatory drugs’ allergy. He also had a past medical history of eosinophilic gastroenteritis/duodenitis (eosinophilia counts >50 cells/high-power field HPF). The use of multiple courses of corticosteroid therapy failed to completely control these conditions. In October 2019, after starting benralizumab (an antibody directed against the alpha chain of the IL-5 cytokine receptor) as add-on treatment for severe eosinophilic asthma, important clinical improvements were reported both on the respiratory (no asthma exacerbations) and gastrointestinal systems (eosinophilia count 0 cells/HPF). Patients’ quality of life also increased. Since June 2020, systemic corticosteroid therapy was reduced without worsening of gastrointestinal symptoms or eosinophilic inflammation. This case warns of the importance of early recognition and appropriate individualized treatment of eosinophilic immune dysfunctions and suggests the conduction of further larger studies on the use of benralizumab in gastrointestinal syndromes aiming at better understanding its relying mechanisms of action in the intestinal mucosa.

show abstract

“…Recently, there have been reports that lung diseases, such as COPD, asthma, lung cancer, and lung fibrosis are associated with gut microbiota dysbiosis [ 16 ]. Notably, COPD is a severe, persistent airway and lung disease; the effectiveness of current treatments is limited and warrants the need for further research on potential therapeutic options [ 17 - 19 ]. This review summarizes the findings of existing research on the association between gut microbiota dysbiosis and the etiology or pathogenesis of COPD, as well as the regulation of the gut microbiota for COPD treatment.…”

Section: Introductionmentioning

confidence: 99%

Gut Microbiome as a Possible Cause of Occurrence and Therapeutic Target in Chronic Obstructive Pulmonary Disease

Lim¹,

Song²,

Shin

2023

J. Microbiol. Biotechnol.

View full text Add to dashboard Cite

As a long-term condition that affects the airways and lungs, chronic obstructive pulmonary disease (COPD) is characterized by inflammation, emphysema, breathlessness, chronic cough, and sputum production. Currently, the bronchodilators and anti-inflammatory drugs prescribed for COPD are mostly off-target, warranting new disease management strategies. Accumulating research has revealed the gut–lung axis to be a bidirectional communication system. Cigarette smoke, a major exacerbating factor in COPD and lung inflammation, affects gut microbiota composition and diversity, causing gut microbiota dysbiosis, a condition that has recently been described in COPD patients and animal models. For this review, we focused on the gut–lung axis, which is influenced by gut microbial metabolites, bacterial translocation, and immune cell modulation. Further, we have summarized the findings of preclinical and clinical studies on the association between gut microbiota and COPD to provide a basis for using gut microbiota in therapeutic strategies against COPD. Our review also proposes that further research on probiotics, prebiotics, short-chain fatty acids, and fecal microbiota transplantation could assist therapeutic approaches targeting the gut microbiota to alleviate COPD.

show abstract

A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils

Cited by 4 publications

References 19 publications

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

The Role of Benralizumab in Eosinophilic Immune Dysfunctions: A Case Report-Based Literature Review

Gut Microbiome as a Possible Cause of Occurrence and Therapeutic Target in Chronic Obstructive Pulmonary Disease

Contact Info

Product

Resources

About